Drugs / AZELOPRAZOLE
last change Mar 2017 re-read 2 minutes ago

AZELOPRAZOLE

Small molecule

Developed for
gastroesophageal reflux disease
Investigated by
Zeria Pharmaceutical · Eisai Inc.

Trials 4 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT02618629 Jan → Jun 2016 Zeria Pharmaceutical Completed No outcome recorded
Phase 1 NCT02509923 Jul 2015 → Mar 2016 Zeria Pharmaceutical Completed No outcome recorded
Phase 1 NCT01390714 Jul → Oct 2011 gastroesophageal reflux disease Eisai Inc. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02463643 May 2015 → Oct 2016 gastroesophageal reflux disease Zeria Pharmaceutical Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as AZELOPRAZOLE ChEMBL registry synonym — accepted as the source's own label CHEMBL4300945
Known as Azeloprazol ChEMBL registry synonym — accepted as the source's own label CHEMBL4300945
Known as AZELOPRAZOLE SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL4300945
Known as E-3710 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL4300945
Known as E3710 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01390714
Known as Z-215 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02463643
2

NCT02618629

NCT02509923

Known as Z-215 FREE ACID ChEMBL registry synonym — accepted as the source's own label CHEMBL4300945
Known as Z-215 SODIUM SALT ChEMBL registry synonym — accepted as the source's own label CHEMBL4300945
Modality Small molecule CHEMBL4300945
Route Oral “following oral administration to Healthy Male Japanese Subjects” NCT01390714